OMER logo

Omeros Corporation (OMER)

$18.63

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on OMER

Market cap

$1.35B

EPS

1.73

P/E ratio

12

Price to sales

34.65

Dividend yield

--

Beta

2.540479

Price on OMER

Previous close

$18.39

Today's open

$18.30

Day's range

$18.07 - $18.73

52 week range

$3.94 - $18.89

Profile about OMER

CEO

Gregory A. Demopulos

Employees

202

Headquarters

Seattle, WA

Exchange

NASDAQ Global Market

Shares outstanding

72388316

Issue type

Common Stock

OMER industries and sectors

Healthcare

Biotechnology & Life Sciences

News on OMER

This Biotech Stock Just Gapped Up To A Five-Year High; Here's Why

Omeros stock rocketed to a five-year high Thursday on blowout second-quarter results for its new treatment for transplant complications.

news source

Investors Business Daily • Aug 13, 2026

news preview

Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript

Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript

news source

Seeking Alpha • Aug 13, 2026

news preview

Omeros Q2 Earnings Call Highlights

Omeros NASDAQ: OMER reported second-quarter net sales of $28.5 million for YARTEMLEA, its newly launched treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA, as the company generated positive operating cash flow and reduced its convertible debt after the quarter ended.

news source

MarketBeat • Aug 13, 2026

news preview

Omeros Corporation Reports Second Quarter 2026 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2026, which include: Second Quarter and Recent Highlights YARTEMLEA®, the first and only approved treatment for stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-lethal complication of stem cell transplantation, generated gross revenues of $32.2 million in the second quarter of 2026, an incre.

news source

Business Wire • Aug 12, 2026

news preview

Omeros (OMER) Q2 Earnings and Revenues Beat Estimates

Omeros (OMER) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.27 per share. This compares to a loss of $0.53 per share a year ago.

news source

Zacks Investment Research • Aug 12, 2026

news preview

Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the second quarter of 2026 on Wednesday, August 12, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company's financial results. Conference Call Details and Webcast Link Instructions To access the live webcast, please.

news source

Business Wire • Aug 10, 2026

news preview

CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for YARTEMLEA® (narsoplimab-wuug) under the Fiscal Year (FY) 2027 Hospital Inpatient Prospective Payment System (IPPS) Final Rule. Beginning October 1, 2026, eligible hospitals treating Medicare patients with YARTEMLEA for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) wi.

news source

Business Wire • Aug 3, 2026

news preview

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

news source

PRNewsWire • Jul 30, 2026

news preview

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER

NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

news source

GlobeNewsWire • Jul 21, 2026

news preview

Omeros Corporation Investigated by the Portnoy Law Firm

LOS ANGELES, July 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Omeros Corporation , (“ Omeros " or the "Company") ( NASDAQ : OMER ) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

news source

GlobeNewsWire • Jul 13, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Omeros Corporation

Open an M1 investment account to buy and sell Omeros Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in OMER on M1